ARS Pharmaceuticals (SPRY) News Today

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares have been under pressure as multiple law firms publicized a securities class action tied to the company’s disclosures about coverage for neffy, its needle-free epinephrine product.

• Neutral Sentiment: Several firms, including Rosen Law Firm notice Rosen, Kaplan Fox, Faruqi & Faruqi, and Bronstein Gewirtz & Grossman, reminded investors of an October 5, 2026 deadline to seek lead-plaintiff status in the federal lawsuit. The action covers investors who purchased SPRY securities from March 9 through June 24, 2026.
• Negative Sentiment: The allegations focus on whether ARS Pharmaceuticals failed to disclose that CVS Caremark’s formulary process could delay a neffy coverage decision until January 2027, potentially causing the product to miss the important summer and back-to-school allergy seasons. One law firm’s notice referenced a 23.9% one-day decline in SPRY shares after the disclosure sequence. SueWallSt investor alert
• Negative Sentiment: The repeated litigation announcements add reputational, legal-cost, and potential financial-liability risks. However, the releases represent allegations, not a court finding that ARS Pharmaceuticals violated securities laws.

The news flow is negative for investor sentiment because it keeps attention focused on potential commercial execution problems for neffy and possible shareholder losses. SPRY has already decreased substantially from its 12-month high and remains below its 50-day and 200-day moving averages, suggesting continued weakness, although the latest articles do not report a new operating result or regulatory decision.